Today, our CEO @Peter Anastasiou will be presenting at the Morgan Stanley Healthcare Conference at 4:05 PM ET in New York. He will share insights into Capsida's approach to gene therapy and our commitment to transforming the treatment landscape for patients with rare and common diseases across all ages. This is a fantastic opportunity to hear firsthand about our progress and future plans as we strive to make the impossible possible for patients. We’re looking forward to connecting with industry leaders and investors at the conference. If you're attending, be sure to catch Peter's presentation! #CapsidaBiotherapeutics #GeneTherapy #HealthcareInnovation #MorganStanleyHC2024 #Biotech
Capsida Biotherapeutics
Biotechnology
Newbury Park, CA 13,185 followers
Engineering novel AAVs and developing the next generation of gene therapies
About us
Capsida Biotherapeutics Inc. is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening genetic disorders. Capsida's technology allows for the targeted penetration of cells and organs, while limiting collateral impact on non-targeted cells and organs, especially the liver. This technology allows for the delivery of the gene therapy in a non-invasive way through intravenous administration. Capsida's technology is protected by a growing intellectual property portfolio which includes more than 30 patent applications and one issued U.S. patent 11,149,256. The company is exploring using the technology across a broad range of life-threatening genetic disorders. Its initial pipeline consists of multiple neurologic disease programs. The company has strategic collaborations with AbbVie and CRISPR, which provide independent validation of Capsida's technology and capabilities. Capsida is a multi-functional and fully integrated biotechnology company with proprietary adeno-associated virus (AAV) engineering, multi-modality cargo development and optimization, translational biology, process development and state-of-the-art manufacturing, and broad clinical development experience. Capsida's biologically driven, high-throughput AAV engineering and cargo optimization platform originated from groundbreaking research in the laboratory of Viviana Gradinaru, Ph.D., a neuroscience professor at the California Institute of Technology.
- Website
-
http://www.capsida.com
External link for Capsida Biotherapeutics
- Industry
- Biotechnology
- Company size
- 51-200 employees
- Headquarters
- Newbury Park, CA
- Type
- Privately Held
- Founded
- 2019
- Specialties
- Biotechnology, AAV Engineering, Gene Therapy, Biopharmaceuticals, Protein Engineering, Analytical Development, Process Development, and AAV Immunology
Locations
-
Primary
1290 Rancho Conejo Blvd
Newbury Park, CA 91320, US
Employees at Capsida Biotherapeutics
Updates
-
Exciting news! In September and October, #Capsida’s management team will be participating in investor and industry conferences hosted by Bank of America, Morgan Stanley, Chardan, and the Mass General Brigham World Medical Innovation Forum in partnership with Bank of America. We’ll be sharing details about Capsida’s innovative pipeline, including recent data from our next-generation intravenously administered gene therapies, for genetic epilepsy due to STXBP1 mutations and Parkinson’s disease associated with GBA mutations. We will also be presenting at the Cell & Gene Meeting on the Mesa on October 8. To learn more, swipe below for conference details and click the link to read our press release: https://lnkd.in/gGP84sr4 #InvestorConferences #GeneTherapyInnovation #CapsidaBiotherapeutics
-
The STXBP1 protein is expressed in each and every neuron and is essential for supporting communication between neurons in the brain. We are proud to be working on a gene therapy that has shown preclinical brain-wide expression of STXBP1 protein and could potentially improve outcomes for patients and families living with genetic epilepsy and developmental encephalopathy due to STXBP1 mutations. Learn more about STXBP1 and how you can support the @STXBP1Foundation and September STXBP1 awareness month at: https://lnkd.in/d-X_hsSA #STXBP1Awareness #SupportSTXBP1 #STXBP1Community #RareDiseaseAwareness #HopeForSTXBP1
-
Today, we pause to honor the dedication, hard work, and innovation of all workers who contribute to building a brighter future. At Capsida, we deeply value the efforts of our team members who bring passion and perseverance to their work every day. It’s through their commitment that we are able to push the boundaries of science and medicine, striving to develop life-changing gene therapies for patients around the world. https://lnkd.in/dK9ejFj #LaborDay #EmployeeAppreciation #GeneTherapy #Innovation
-
As we turn the page on August, Capsida is looking ahead to #STXBP1 awareness month in September. Genetic epilepsy and developmental encephalopathy due to STXBP1 mutations is a neurodevelopmental condition estimated to affect one in 30,000 children born each year globally. There are no disease-modifying therapies for this disorder. At Capsida, we are working on a gene therapy that could potentially improve outcomes for patients and families dealing with this devastating condition. Learn more about STXBP1 and how you can support the STXBP1 Foundation and September STXBP1 awareness month at: https://lnkd.in/d-X_hsSA
-
We are excited that our VP of clinical development, Melanie Brandabur M.D., will participate in a webinar on September 4th, focused on innovations in gene therapies for Parkinson’s disease, hosted by Cure Parkinson’s. The event is presented in partnership with the Journal of Parkinson’s Disease and chaired by the University of Edinburgh’s Professor Tilo Kunath. The webinar takes place Wednesday, September 4th, 12-1 pm EST. We hope that you can join! You can register here: https://lnkd.in/gWKbYi_E #GeneTherapy #ParkinsonsResearch #Innovation
-
Thank you, Caroline Jewett for speaking with our Capsida Women's Alliance (CWA) on August 15th! Caroline, Head of Quality at Genelux Corporation, shared valuable insights on her career journey, the distinctions between mentoring and coaching, and strategies for navigating today's dynamic industry. Her perspective was truly inspiring and sparked great discussion within our group. The Capsida Women's Alliance is one of our employee-led resource groups, dedicated to creating and maintaining an inclusive space for all female employees. The group focuses on addressing career and personal issues relevant to women, spotlighting accomplishments in science and business, and establishing a resource for female perspectives and mentoring within the company. What key insights have you gained from mentoring or coaching in your career? Tell us in the comments below! #Leadership #Management #WomenInLeadership #WomenInSTEM #DiversityAndInclusion #WorkplaceEquality #InItTogether
-
Capsida Biotherapeutics reposted this
Proud for Capsida Biotherapeutics to be featured as one of the top 10 neuroscience biotechs…
We are pleased to be featured in Labiotech.eu's roundup of top neuroscience biotech companies. This recognition highlights our dedication to advancing gene therapies for neurological disorders. It’s an exciting time for the field, and we’re proud to be a leading innovator driving progress in neuroscience. #neuroscience #genetherapy #biotech #innovation
-
We are pleased to be featured in Labiotech.eu's roundup of top neuroscience biotech companies. This recognition highlights our dedication to advancing gene therapies for neurological disorders. It’s an exciting time for the field, and we’re proud to be a leading innovator driving progress in neuroscience. #neuroscience #genetherapy #biotech #innovation
10 neuroscience biotech companies you should know about
https://www.labiotech.eu
-
This summer, we had the incredible opportunity to host a talented group of interns from Moorpark College. Our interns dove headfirst into the world of gene therapy, gaining hands-on experience in our lab and contributing to our mission of unlocking the potential for gene therapy for all. We are thrilled to see the passion and dedication these students bring to their work. They developed valuable skills and insights while making meaningful contributions to our projects and pushing the boundaries of what's possible in gene therapy. It's been an enriching experience! As we wrap up the summer internship, we’re excited to continue this journey into the fall, nurturing the next generation of innovators and leaders in the field of gene therapy. 📸 Check out some snapshots of our interns in action and a group photo capturing the spirit of collaboration and learning! #GeneTherapy #Internship #Biotech #MoorparkCollege #Capsida #STEMEducation #InItTogether #DrivenByCuriosity #InnovationMeetsExecution